Meet the Next-Gen Psychedelic Treating Alcoholism | Is this the Future of Addiction Treatment?

In today’s episode of PsycBiz, James —the Psychedelic Investor— sits down with Mark Haden, VP of Business Development for Clearmind Medicine (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0).

Clearmind is a next-gen psychedelics company working on treating addiction. Their main candidate is a next-gen psychedelic called MEAI. Currently, MEAI is being researched as a treatment for various forms of addiction, including Alcohol Use Disorder.

Though Clearmind’s MEAI is in its early stages, both pre-clinical results and anecdotal evidence suggests that it will be effective. The company plans to launch a phase 1 safety trial by the end of this year.
Mark Haden is a wonderful presenter, and I hope you enjoy this episode.

Before working with Clearmind, he worked at MAPS.

#Alcoholism #Addiction #Psychedelics

source

Similar Posts

Ask a Psychotherapist With Kelli Foulkrod
March 3, 2021June 2, 2024 Listen, Podcasts

We debut our first ever “Ask a Psychotherapist” segment where we take questions submitted by our listeners and have Kelli Foulkrod, a transpersonal psychotherapist, answer them.
University of Wisconsin-Madison Launches New Psychedelic Research Center
August 24, 2021June 2, 2024 Learn, Research

This school offers the first accredited American degree focused on the study and therapeutic development of psychedelic compounds and related psychoactive drugs.
American Overdose Deaths Reach Record High During COVID Pandemic—And New Study Shows Psychedelics Can Help
November 17, 2021June 2, 2024 Learn, Research

“After adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use,” researchers say.
Interview With Douglas K. Gordon
April 21, 2021June 2, 2024 Listen, Podcasts

CEO of Silo Wellness, Douglas K. Gordon, speaks about the company’s expansion to the Frankfurt Exchange and the recent collaboration with the Bob Marley Estate.
How To Reduce Anxiety and Depression By Fixing Nervous System Dysregulation
April 19, 2023June 2, 2024 Listen, Podcasts, Research

The good news is that if we can get the nervous system unstuck, we’ll stop feeling so anxious and depressed. Thankfully, there are some fantastic tools for fixing nervous system dysregulation.
Numinus & Cybin Forge MASSIVE DEALS ( NUMI / CYBN )
July 9, 2021June 2, 2024 Listen, Videos

BIG news for Cybin Inc. (CYBN: NEO) (CLXPF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF: OTC).

First and foremost, Numinus announced that the company acquired NCT, a Toronto-based, fully operational neurology center with 13 doctors, 8 allied health staff, nurse practitioners, and physician assistants. NCT and Numinus plan to establish the first center for excellence in psychedelic neurology.

Speaking of centers of excellence, Cybin entered into an agreement with a company called Greenbrook TMS to establish mental health centers of excellence in order to facilitate R & D of psychedelic compound-based therapeutics for patients suffering from depression.

Why is this big news? Watch till the end to find out!

In other news, we are glad to announce that The Psychedelic Investor has entered into a collaboration with Psychedelic Spotlight, one of the biggest news sources for psychedelic-related news.

Twice a month, I will be discussing some of the major industry news among other psychedelic industry experts in Psychedelic Spotlight’s segment titled: “Spotlight Roundup”.

Check out my first appearance on their podcast by clicking the link below!
https://www.youtube.com/watch?v=UKGFXnsOlr8

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Timestamps
0:00 -Intro
2:40 – Numinus Acquisition of Neurology Center of Toronto
9:55 -Cybin Enters Agreement with Greenbrook

Links:

NUMINUS WELLNESS TO ACQUIRE NEUROLOGY CENTRE OF TORONTO, PLANS TO CREATE CENTRE FOR PSYCHEDELIC NEUROLOGY:
https://thepsychedelicinvestor.com/2021/07/06/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology/

CYBIN (NEO: CYBN, OTC: CLXPF) ENTERS INTO COLLABORATION AGREEMENT WITH GREENBROOK TMS TO ESTABLISH MENTAL HEALTH CENTERS OF EXCELLENCE:
https://thepsychedelicinvestor.com/2021/07/08/cybin-enters-into-collaboration-agreement-with-greenbrook-tms-to-establish-mental-health-centers-of-excellence/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #Cybin #NUMIStock